NeOnc Lands New Coverage and Roth Sees Potential 2026 Trial Catalyst

GlobeNewswire Inc. | Sep 24, 2026 10:20 AM EDT

NeOnc (NASDAQ: NTHI) picks up fresh Wall Street coverage, at a pivotal moment, with a Buy rating and $20 price target